(b) Serum-starved A431 and MDA-MB-231 cells were pretreated with DMSO or MK-2206 (5 M) for 2 h and then stimulated with or without EGF (100 ng/ml) for 24 h.
(c) Serum-starved U251 cells were pretreated with DMSO or MK-2206 (5 M) for 2 h and then stimulated with or without IGF (50 ng/ml) or FGF (50 ng/ml) for 24 h.
(d) U87/EGFRvIII cells were pretreated with DMSO or MK-2206 (5 M) for 2 h and then treated with CHX (100 g/ml) for the indicated periods of time. Quantification of PFKP levels relative to tubulin levels is shown. Data represent the means ± SD of 3 independent experiments. *P < 0.01, based on the Student's t test.
(e) 293T cells were transfected with HA-tagged control vector or HA-Myr-AKT1 and then treated with CHX (100 g/ml) for the indicated periods of time. Quantification of PFKP levels relative to tubulin levels is shown. Data represent the means ± SD of 3 independent experiments. *P < 0.01, based on the Student's t test. (c) Serum-starved U87/EGFR cells were stimulated with or without EGF (100 ng/ml) for 30 min.
Immunoprecipitation analyses were performed with an anti-PFKP antibody.
(d) S386 in human PFKP protein is conserved in other species. Serine residues are highlighted in red.
(e) Serum-starved U251 cells were stimulated with or without EGF (100 ng/ml) for 60 min.
Immunoprecipitation with an anti-PFKP antibody was followed by immunoblotting analyses with an anti-phospho-PFKP S386 antibody in the presence or absence of specific blocking phosphopeptides. Immunoblotting analyses were performed with the indicated antibodies (a-d, g-k) . experiments. *P < 0.01, based on the Student's t test.
(j) SFB-TRIM21-expressing U251 cells were pretreated with DMSO or MK-2206 (5 M) for 2 h and then stimulated with or without EGF (100 ng/ml) for the indicated periods of time. A pulldown assay was performed.
(k) U87/EGFRvIII cells were transfected with SFB-TRIM21 and then treated with DMSO or MK-2206 (5 M) for 2 h. A pull-down assay was performed.
